Exploring Predictive Biomarkers for ADC Drug-Induced Pulmonary Toxicities: The Enhertu Experience

• Overviewing biomarkers for ADC drug induced pulmonary toxicities
• Bridging non-clinical toxicology findings and clinical translational safety research
• Case study: Assessing ILD concerns in HER2- targeted ADCs to explore how biomarkers in blood helping refine prediction and how can we monitor and treat ADC toxicities

Speakers:

Zenta Tsuchihashi

Senior Director, Translational Patient Safety, Clinical Safety & Pharmacovigilance

Daiichi Sankyo